Public health agency The U.S. Food and Drug Administration Thursday granted approval of the marketing of the Tandem Diabetes Care t:Slim X2 insulin pump with interoperable technology (interoperable t:Slim X2) for delivering insulin for children and adults with diabetes, through the de novo premarket review pathway.
The US FDA announced the marketing authorisation of the t:Slim X2 insulin pump with the interoperable technology to Tandem Diabetes Care Inc.
Based on the review of the interoperable t:Slim X2 pump performance data, the device can dose insulin accurately and reliably and at the rates and volumes programmed by the user. The US FDA assessed the ability of the pump to communicate with external devices with appropriate reliability, cybersecurity and fail-safe modes.
Additionally, the company's interoperable t:Slim X2 pump works by delivering insulin under the skin at set or variable rates. It can be digitally connected to automatically communicate with and receive drug dosing commands from the AID systems, which typically consist of a pump CGM and software to control the system.
According to the agency, the new the Tandem Diabetes Care t:Slim X2 insulin pump is the first interoperable pump that allows patients to tailor their diabetes management to their individual device preferences.Diabetes therapy systems may be comprised of an ACE insulin pump and other compatible medical devices, including automated insulin dosing (AID) systems, continuous glucose monitors (CGMs), blood glucose meters or other electronic devices used for diabetes management.
Nearly 10% of Americans are diagnosed with diabetes, which impairs the body's ability to make or properly use the blood glucose-regulating hormone insulin.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML